← Back to Screener
aTyr Pharma, Inc. Common Stock (ATYR)
Price$0.83
Favorite Metrics
Price vs S&P 500 (26W)-19.72%
Price vs S&P 500 (4W)-2.42%
Market Capitalization$82.63M
All Metrics
Book Value / Share (Quarterly)$0.69
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-73.65%
Cash Flow / Share (Quarterly)$-0.63
Price vs S&P 500 (YTD)4.97%
Net Profit Margin (TTM)-13549.47%
EPS (TTM)$-0.80
10-Day Avg Trading Volume0.95M
EPS Excl Extra (TTM)$-0.80
Revenue Growth (5Y)-55.14%
EPS (Annual)$-0.80
ROI (Annual)-108.41%
Net Profit Margin (5Y Avg)-16223.90%
Cash / Share (Quarterly)$0.80
ROA (Last FY)-79.69%
Revenue Growth TTM (YoY)-19.15%
EBITD / Share (TTM)$-0.79
ROE (5Y Avg)-70.24%
Operating Margin (TTM)-14076.32%
Cash Flow / Share (Annual)$-0.63
P/B Ratio1.22x
P/B Ratio (Quarterly)1.14x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-123.28x
ROA (TTM)-74.41%
EPS Incl Extra (Annual)$-0.80
Current Ratio (Annual)5.30x
Quick Ratio (Quarterly)5.25x
3-Month Avg Trading Volume1.72M
52-Week Price Return-72.00%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)434.88x
Asset Turnover (Annual)0.00x
52-Week High$7.29
Operating Margin (5Y Avg)-17182.53%
EPS Excl Extra (Annual)$-0.80
CapEx CAGR (5Y)-17.54%
26-Week Price Return-15.73%
Quick Ratio (Annual)5.25x
13-Week Price Return23.38%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)5.30x
Enterprise Value$72.774
Revenue / Share Growth (5Y)-71.90%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-39012.11%
Cash / Share (Annual)$0.80
3-Month Return Std Dev91.49%
Net Income / Employee (TTM)$-1
ROE (Last FY)-109.84%
Net Interest Coverage (Annual)-212.81x
EPS Basic Excl Extra (Annual)$-0.80
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-0.80
ROI (TTM)-98.17%
P/S Ratio (TTM)434.88x
Pretax Margin (5Y Avg)-16224.82%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-101.83%
Year-to-Date Return7.61%
5-Day Price Return12.36%
EPS Normalized (Annual)$-0.80
ROA (5Y Avg)-52.83%
Net Profit Margin (Annual)-39009.47%
Month-to-Date Return8.04%
EBITD / Share (Annual)$-0.79
Operating Margin (Annual)-40856.32%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-69.13%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.80
P/B Ratio (Annual)1.14x
Pretax Margin (TTM)-13550.53%
Book Value / Share (Annual)$0.69
Price vs S&P 500 (13W)22.69%
Beta0.73x
Revenue / Share (TTM)$0.00
ROE (TTM)-99.62%
52-Week Low$0.64
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.69
3.69
3.71
3.69
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ATYRaTyr Pharma, Inc. Common Stock | 434.88x | -19.15% | — | — | $0.83 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
aTyr Pharma develops biotherapeutics using a proprietary tRNA synthetase platform. Its lead candidate, efzofitimod, is a clinical-stage treatment that targets NRP2 to address chronic inflammation and fibrosis, particularly in lung disease. The approach exploits a novel mechanism based on the extracellular signaling pathways of tRNA synthetases.